Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

25.50 -0.38 (-1.45%)
Streaming Delayed Price Updated: 11:20 AM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
From Pomerantz LLP
Via GlobeNewswire
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss. 
Via Benzinga
Topics Intellectual Property
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT
From Pomerantz LLP
Via GlobeNewswire
NIKE, Datadog And Snap Are Among Top 11 Large Cap Gainers Last Week (June 30-July 4): Are The Others In Your Portfolio?
11 best performing large-cap stocks last week, including Symbotic, Nike, First Solar, Datadog, HPE, Summit Therapeutics, Carnival, POSCO, Wynn Resorts, SharkNinja, and Snap 
Via Benzinga
2 Soaring Stocks With More Upside Potential to Buy and Hold
Via The Motley Fool
Why AstraZeneca Stock Got Thumped on Thursday
Via The Motley Fool
Why Summit Therapeutics Stock Soared 8% Higher Today
Via The Motley Fool
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
Via Benzinga
AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report
While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, Bloomberg reported, while noting that... 
Via Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Via ACCESS Newswire
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
From Summit Therapeutics Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT
From Pomerantz LLP
Via GlobeNewswire
Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)
With clinical catalysts on the horizon and a seasoned biotech insider doubling down, Could Nuvectis Pharma (NASDAQ:NVCT)* Become the Next Summit Therapeutics (NASDAQ: SMMT)? 
Via News Direct
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT
From Pomerantz LLP
Via GlobeNewswire
2 Dividend Stocks to Buy and Never Sell
Via The Motley Fool
Topics Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT
From Pomerantz LLP
Via GlobeNewswire
Why Summit Therapeutics Stock Tanked Today
Via The Motley Fool
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
From Pomerantz LLP
Via GlobeNewswire
Why Casey's General Stores Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT
From Pomerantz LLP
Via GlobeNewswire
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
2 Soaring Stocks Wth More Upside Potential
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.